logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Keshu Zhou

the affiliated cancer hospital of zhengzhou university and henan cancer hospital
H指数:23
被引数:2,416

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study

zanubrutinib单药治疗<i>CD79B</i>突变复发或难治性弥漫大B细胞淋巴瘤：一项多中心二期研究

HemaSphere
IF14.6
2026-10-170
OAAI
Li Wang; Keshu Zhou; Fei Li; Qingyuan Zhang; Hui Zhou; Ou Bai; Liping Su; Chunhong Hu; Zhi-Ming Li; Kaiyang Ding; Qunyi Guo; Xiaoling Li; Xiaoxi Zhou; Wenjuan Yu; Shuhua Yi; Zhixia Wei; Wenbin Qian; Feiheng Chen; Guohui Cui; Zhiyu Liang; Qingchao Zeng; Jiaoyan Lyu; Yang Liu; Pan Zhang; Zhirong Shen; Zaixing Shi; Jing Rong; Wei-Li Zhao
Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults

II期研究：评估Relmacabtagene autoleucel（CD19 CAR-T）治疗中国成人复发/难治性套细胞淋巴瘤的疗效

Blood Advances
IF7.1
2025-11-100
OAAI
Yan Xie; Ke-Shu Zhou; Lan-Fang Li; Ai-Bin Liang; Heng Mei; De-hui Zou; Wen-Yu Li; Jie Jin; Zheng-Ming Jin; Hong-Mei Jing; Hai-Yan Yang; Tong Chen; Hui-Qiang Huang; Peng-Cheng He; Jun-Ning Cao; Zhen Xia; Yong-En Gu; Yi-Bei Zang; Zi-Song Zhou; Zhao-Zhao Tian
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study

Glofitamab与真实世界方案在中国接受三线或更后线治疗的复发/难治性弥漫大B细胞淋巴瘤患者中的比较：一项外部对照研究

CANCER BIOLOGY & MEDICINE
IF8.4
2025-09-010
OAAI
Zhou, Keshu; Wu, Huijing; Zhao, Xia; Tan, Xiaohong; Yan, Xiaojing; Liu, Haisheng; Su, Liping; Lan, Yukun; Xu, Jaihui; Zhou, Xiaohui; Shuang, Yuerong; Zhang, Huilai
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study

Tazemetostat（一种EZH2抑制剂）在中国复发性/难治性滤泡性淋巴瘤患者中的有效性和安全性：一项多中心、单臂、Ⅱ期研究

eClinicalMedicine
IF10
2025-08-180
PREAI
Junning Cao; Guangliang Chen; Lihua Qiu; Liling Zhang; Ming Jiang; Ying Cheng; Qiaohua Zhang; Lihong Liu; Ping Li; Yuerong Shuang; Huaqing Wang; Hongwei Xue; Huijing Wu; Meifang Zheng; Keshu Zhou; Zhiming Li; Hongmei Jing; Wei Yang; Zunmin Zhu; Wenyu Li; Jiaxuan Wangwu; Heyu Huang; Qiantao Jia; Dongmei Chen; Songhua Fan; M. Ming Shi; Weiguo Su
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

结外弥漫性大B细胞淋巴瘤：来自多中心EXPECT研究的临床与分子洞察及生存结局

Cancer Communications
IF24.9
2025-05-080
OAAI
Si-Yuan Chen; Peng-Peng Xu; Ru Feng; Guo-Hui Cui; Li Wang; Shu Cheng; Rong-Ji Mu; Hui-Lai Zhang; Xiao-Lei Wei; Yong-Ping Song; Kai-Yang Ding; Li-Hua Dong; Zun-Min Zhu; Shen-Miao Yang; Xin Wang; Ting-Bo Liu; Jian-Da Hu; Xiao-Yun Zheng; Ou Bai; Jing-Yan Xu; Liang Huang; Wei Sang; Ke-Qian Shi; Fan Zhou; Fei Li; Ai-Bin Liang; Hui Zhou; Si-Guo Hao; Hong-Hui Huang; Bin Xu; Wen-Bin Qian; Cai-Xia Li; Zhi-Ming Li; Chong-Yang Wu; Xiao-Bo Wang; Wen-Yu Shi; Shu-Ye Wang; Yu-Yang Tian; Xi Zhang; Ke-Shu Zhou; Li-Juan Cui; Hui Liu; Huo Tan; Qing Leng; Dong-Lu Zhao; Ting Niu; Wei-Li Zhao
Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Axicabtagene Ciloleucel（Axi-cel）治疗复发/难治性非霍奇金淋巴瘤的疗效与安全性：中国人群真实世界数据

BLOOD
IF23.1
2024-11-050
PRE
Yan, Zixun; Zou, Dehui; Qian, Wenbin; Lu, Ying; Li, Yuhua; Ji, Dongmei; Zhu, Xiaojian; Mei, Heng; Li, Ping; Qu, Changju; Zhang, Lei; Zhou, Keshu; Jing, Hongmei; Niu, Ting; Ji, Chunyan; Li, Lanfang; Yang, Hua; Li, Fei; Wang, Wei; Xu, Kailin; Zhao, Jinghua; Wu, Depei; Hu, Yu; Zhao, Weili
Effect Analysis of 33 Patients with Corticosteroids Resistant Grade III/IV Acute Liver Graft-Versus-Host Disease Treated with Sequential Low-Dose Cyclophosphamide and Anti-Thymocyte Globulin Following Plasma Exchange

33例对皮质类固醇耐药的III/IV级急性肝移植物抗宿主病患者在血浆置换后序贯应用低剂量环磷酰胺和抗胸腺细胞球蛋白治疗的疗效分析

BLOOD
IF23.1
2024-11-050
PRE
Wang, Juan; Zu, Yingling; Gui, Ruirui; Li, Zhen; Zhang, Wenli; Xin, Xiangke; Zhang, Yanli; Lu, Wenyi; Fu, Yuewen; Zhou, Keshu; Zhou, Jian
SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

SG301，一种新型抗CD38单克隆抗体，在复发/难治性多发性骨髓瘤患者中的研究：一项首次人体、多中心、I期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Tian, Ying; Zhou, Keshu; Lin, Quande; Qian, Wenbin; Yang, Wei; Sao, Li; Yuan, Guolin; Yan, Xiaojing; Ma, Liangming; Zhou, Xin; Liu, Lihong; Zhu, Fangbing; Zuo, Xuelan; Du, Xin; Ji, Xu; Zhang, Xuzhao; Shen, Jing; Zhou, Hai; Li, Na; Chen, Wenming
Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

CS5001的安全性及有效性：一项全球性I期a/b、首次人体试验研究，该研究针对接受新型抗ROR1 ADC治疗的晚期淋巴瘤患者。

BLOOD
IF23.1
2024-11-050
PRE
Song, Yuqin; Zhang, Jian; Zhou, Keshu; Zhang, Liling; Barve, Minal; Lemech, Charlotte; Li, Wenyu; Cherng, Hua-Jay J.; Huang, He; Xie, Linna; Zuniga, Richard; Zhou, Caicun; Shen, Lin; Yang, Shujun; Bishnoi, Sarwan; Zhang, Yan; Wang, Jingru; Zhu, Xiaoli; Li, Eei; Yang, Jason
Preliminary Efficacy and Safety of the CK1e/PI3KS Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

HZ-H08905-101研究：CK1e/PI3KS双抑制剂HZ-H08905在复发和/或难治性外周T细胞淋巴瘤患者中的初步疗效与安全性结果

BLOOD
IF23.1
2024-11-050
PRE
Wei, Juying; Yu, Wenjuan; Jin, Zhengming; Zhou, Keshu; Yang, Haiyan; Li, Fei; Li, Lanfang; Zhang, Bo; Hu, Miao; Zhang, Yanping; Zhou, Xinglu; Jin, Jie
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE

zanubrutinib与ibrutinib在中国复发/难治性慢性淋巴细胞白血病 (R/R CLL) 患者中的疗效和安全性得到改善: 高山亚组

ANNALS OF HEMATOLOGY
IF2.4
2024-06-184
OAAI
Zhou, Keshu; Wang, Tingyu; Pan, Ling; Xu, Wei; Jin, Jie; Zhang, Wei; Hu, Yu; Hu, Jianda; Feng, Ru; Li, Ping; Liu, Zhougang; Liu, Peng; Jing, Hongmei; Gao, Sujun; Zhang, Huilai; Yu, Kang; Wang, Zhao; Zhu, Xiongpeng; Sun, Zimin; Li, Fei; Yan, Dongmei; Weng, Jianyu; Fu, Lina; Wang, Liping; Salmi, Tommi; Wu, Kenneth; Qiu, Lugui

研究方向

暂未获取到该数据
J
Jianda Hu
H 指数:36论文数:475被引数:6,561
H
Huilai Zhang
H 指数:37论文数:375被引数:5,131
Y
Yongping Song
H 指数:44论文数:427被引数:8,747
S
Sujun Gao
H 指数:25论文数:207被引数:2,216
W
Wei Xu
H 指数:42论文数:662被引数:7,658
H
Haiyan Yang
H 指数:24论文数:150被引数:2,133
Y
Yu Hu
H 指数:79论文数:779被引数:3.3万
D
Dehui Zou
H 指数:29论文数:512被引数:3,138
Z
Zhiming Li
H 指数:29论文数:351被引数:3,419
K
Kaiyang Ding
H 指数:18论文数:151被引数:1,135